Articles On Noxopharm (ASX:NOX)

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Noxopharm (NOX) publishes preliminary data from its IONIC investigator-initiated pilot trial for its oncology drug Veyonda IONIC is exploring Veyonda’s potential to increase the efficiency of Opdivo, an immune inhibitor used to treat so...

Immutep gets US FDA clearance to start Phase 1 study Noxopharm says its Sofra platform is effective against inflammatory skin disease Epsilon Healthcare announced a new CEO   US FDA approves Imugene’s Phase 1 Immuno-oncology biotech Imug...

The ASX is expected to open slightly higher on Friday as reports suggest the US debt ceiling talks could be resolved within the coming days. It comes off the back of President Biden reassuring Americans yesterday the country would “not...

The ASX is set to open higher on Friday after a Wall Street rally overnight FAANG stocks lifted, while Alibaba said it was considering an IPO and a spinoff The US Fed is considering whether it should skip a meeting in June   Aussie shares...

The ASX 200 benchmark has posted a solid slab of gains, up 0.78% for the day Energy and Materials have teamed up to bring the winnings, at +2.5% and +1.6% respectively Creso Pharma’s buy-out of HHI delivers strong backing from investors, u...

The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Health care stocks have surged in early trade, up more than a per cent. Biotech company Immuron made the most of the boost, with its shares up more than 21 per cent after posting its Q3 FY23 financial figures. Global sales of its trav...

Noxopharm plunged 45pc after scaling down its Veyonda program Rhythm Biosciences rose 25pc after saying that ColoSTAT will be presented at a prestigious gathering Immuron surged 24% as global sales rose significantly   Noxopharm (ASX:NOX)...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Noxopharm (NOX) prioritises the development of its two “cutting-edge” preclinical technology platforms moving forward – Chroma and Sofra The company will discontinue its two Veyonda trials, due to protracted timelines, low patient accept...

The ASX is expected to slip on Thursday as eyes are once again on the Reserve Bank. The RBA is expected to deliver its financial stability review in the coming hours, ahead of the Easter long weekend. Here are some ASX-listed companie...

The ASX jumped 0.3% after lunch as the RBA finally kept rates on hold. XGD All Ordinaries Gold soared ~3.0% because someone missed a memo. Besra Gold is back on top with a 36% leap after Quantum’s cheque cleared customs.   Local markets w...

Noxopharm has developed a new product candidate based on mRNA technology IDT nabs TGA licence extension to manufacture advanced injectable therapies PharmAust patient in motor neurone disease trial elevated to Cohort 2   Biotech company N...

Noxopharm (NOX) is developing a new mRNA “vaccine enhancer” product to improve the effectiveness of vaccines and reduce inflammation The company says it has selected a lead candidate for further development, and the product — dubbed SOF-...

Noxopharm (ASX:NOX) has announced the development of a new product candidate based on mRNA technology as part of the company’s Sofra preclinical platform.

The ASX is expected to open higher on Tuesday after the mood surrounding the ongoing banking turmoil eased overnight and bank stocks rose. A significant player in this was North Carolina-based First Citizens, which entered an agreement t...

The ASX is poised to open higher on Tuesday US energy and bank stocks led Wall Street overnight Binance and CEO CZ were sued by the CFTC   The ASX is set to rise at the open on Tuesday. At 7.30am AEDT, the ASX 200 April futures contract w...

The ASX climbed 0.4% today after investors threatened it with a stick Mt Monger (ASX:MTM) wins the day by securing funding for it’s Canadian REE play New consumer survey suggests 42% of shoppers might be dumber than previously feared   Au...

Noxopharm (ASX:NOX) has announced that research from its inflammation-related Sofra preclinical program will be presented orally at the upcoming 15th International Congress on Systemic Lupus Erythematosus.

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Noxopharm (NOX) is set to progress to part two of its clinical trial of drug candidate Veyonda to treat prostate cancer Safety data from the company’s third cohort of patients in its DARRT-2 trial was reviewed by the Safety Steering Comm...

The ASX is set to end its four-day winning streak today The World Economic Forum began overnight Bitcoin keeps climbing to pre-FTX levels   Aussie shares are set to drift lower on Tuesday, ending a four-day winning streak. At 8am AEDT, th...

The ASX is poised to fall sharply on Friday following a plunge on Wall Street Nasdaq fell by more than 3% overnight The BoE and ECB hikes rates by 50bp   Local shares are set to fall sharply on Friday as US tech stocks plummeted overnight...

Australian company Noxopharm (ASX:NOX) has provided an update on the IONIC Investigator-initiated pilot Phase 1 clinical trial of its lead oncology drug candidate Veyonda.

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Noxopharm (NOX) receives a $5.01 million rebate under the Australian Government’s Research and Development (R&D) Tax Incentive scheme for expenditure during FY22CEO Gisela Mautner says the rebate will go towards supporting the company’s...

Avita Medical successfully achieved two co-primary endpoints Noxopharm received $5.011 million in R&D rebate Avita makes crucial progress in pivotal trial Avita Medical (ASX:AVH) announced that it has achieved the co-primary endpoints...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Noxopharm (ASX:NOX) has announced the resignation of founder Dr Graham Kelly as a non-executive director in a move it describes as a natural evolution.

Wall Street slump leads the ASX into an early morning drop. Thanks, Obama Benchmark strides deeper into the red, graceful as a moose on rollerskates New Age Exploration has a mystical moment at the peak of Mount Profit Well, it’s safe to...

Noxopharm (ASX:NOX) has announced what it describes as encouraging new preclinical data from its long-term collaboration with UNSW Sydney.

Biotron commences human trial of COVID-19 Pancreatic trial news from Noxopharm and Clarity Pharma Vectus completes dosing of last cohort   Biotron (ASX:BIT) jumped 6% this morning after announcing the start of a human trial of its lead an...

Local shares will open much lower on Wednesday after a big plunge on Wall Street US CPI came in higher than expected Bitcoin slumps 10pc Local shares are set to plunge on Wednesday morning after a big selloff on Wall Street overnight. At...

Noxopharm (NOX) reports “encouraging” new preclinical data from a dual-cell therapy pancreatic cancer studyThe company received results from its collaboration with UNSW Sydney, where Noxopharm conducted an 18-month trial to test a new drug,...

ASX 200 sinks 2% Small caps get crushed, down 2.5%  Region, AUD and miners sink on weaker China activity   The local market is being dragged to hell by mining, materials and gold stocks, which are down between 4% and 5%. The S&P/ASX...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Noxopharm (ASX:NOX) has announced the addition of three US sites for its CEP-2 sarcoma study - Washington University in St Louis and two Mayo Clinic sites in Florida and Minnesota.

The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

ASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since February 22 Tuesday winners: ResApp (ASX:RAP), RiversGold (ASX:RGL)    The ASX Emerging Companies (XEC) index is 1.5% higher in late trade....

Noxopharm’s (NOX) lead oncology drug Veyonda has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) Veyonda is used to treat soft tissue sarcoma, a broad term for cancers that start in the soft tissues...

An ASX healthcare share is racing into the green today following an update from the US Food and Drug Administration (FDA). The Noxopharm Ltd (ASX: NOX) share price has rocketed 17.19% today and is currently at 38 cents. In earlier trade,...

Highlights The ASX Small Ordinaries index was seen 0.49% up at 3,293.2, by 12:30 PM AEDT. RAP, RGL and NOX were three ASX penny stocks delivering high returns today. Making a consistent gain from penny stocks is not an easy task and i...